flow semaglutide trial Johannes Mann ending with a plug for the trial, the only dedicated renal outcome testing the effect of GLP1-RA (semaglutide) on a primary outcome of 50% decline in eGFR/ESKD/renal death # ๐จ#FLOW: The most anticipated trial
Description
If more than 5 days have elapsed, skip the dose and resume your normal schedule the following week
Focus on consistent hydration, balanced fiber intake, and regular eating patterns to help regulate function
Weight Loss Clinic Winter Haven: Finding the Best Fit for You Embarking on a weight loss journey can be challenging
Stress actually makes hot flashes worse
Understanding whether semaglutide plays a role in causing palpitations and whether these episodes are a cause for concern is essential for people taking this medication or considering it as part of their treatment plan
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
